Abstract 1693: Targeting MET-LGR5 crosstalk using an antibody-drug conjugate combination with diverse payloads to overcome adaptive resistance in colorectal cancer

作者
Shraddha Subramanian,Peyton C. High,Zhengdong Liang,Cara Guernsey-Biddle,Adela M. Aldana,Kendra S. Carmon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 1693-1693
标识
DOI:10.1158/1538-7445.am2026-1693
摘要

Abstract Off-target side effects and drug resistance often hamper the therapeutic benefits of existing anti-cancer therapies against colorectal cancer (CRC), the second deadliest malignancy worldwide. CRCs contain tumor-initiating cancer stem-like cells (CSCs) that survive toxic drugs and give rise to metastatic disease. Antibody-drug conjugates (ADCs) are a revolutionary class of therapeutics that leverage monoclonal antibody (mAb) specificity to deliver cytotoxic payloads to tumor cells. We generated ADCs targeting leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), a bona fide CSC biomarker frequently overexpressed in CRCs. Our LGR5 ADC exhibited high potency in CRC xenograft models with minimal toxicity. However, it failed to prevent tumor relapse after treatment cessation. Interestingly, we found that recurrent tumors evade LGR5 ADC-mediated elimination by transiently converting into an LGR5-negative (LGR5-) state, accompanied by concomitant MET upregulation and activation of the downstream pathway. MET is a receptor tyrosine kinase frequently upregulated in CRCs and promotes metastatic progression. We identified that the activation of STAT3, a downstream effector protein in the MET pathway, undermines LGR5 ADC efficacy in CRC cells. To eliminate drug-resistant LGR5- cells, we generated MET-targeted ADCs by attaching a highly selective MET mAb (ABT700) backbone to the DNA-crosslinking payload pyrrolobenzodiazepine (PBD) via site-specific conjugation. This MET ADC (ABT700-PBD) demonstrated dose-dependent cytotoxicity in CRC cells. Furthermore, ABT700-PBD did not affect CRC cells with genetically induced MET ablation, demonstrating its specificity. Safety studies in immunocompetent mice showed that ABT700-PBD exhibited a favorable safety profile. Moreover, in CRC xenograft models, ABT700-PBD induced marked tumor regression. However, in the residual tumors following dose-dependent ABT700-PBD monotherapy, LGR5 protein expression was upregulated. These observations suggest that the MET-LGR5 crosstalk may be a potential driver of adaptive resistance in CRC. Cytotoxicity assays testing ABT700-PBD and our previously reported camptothecin-derived (CPT2) LGR5-targeted ADC (8E11-CPT2) demonstrated synergistic cell-killing activity in vitro. Combination treatment with ABT700-PBD and 8E11-CPT2 in CRC patient-derived xenograft models extended survival compared to single-agent ADCs. Collectively, our findings support MET and LGR5 ADC combination therapy as a novel treatment strategy to overcome adaptive resistance-driven relapse in CRC. Citation Format: Shraddha Subramanian, Peyton Christian High, Zhengdong Liang, Cara Guernsey-Biddle, Adela Aldana, Kendra S. Carmon. Targeting MET-LGR5 crosstalk using an antibody-drug conjugate combination with diverse payloads to overcome adaptive resistance in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1693.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yu发布了新的文献求助10
1秒前
cdercder的应助被开心德地采纳,获得10
1秒前
贾贡献的应助被学术bug采纳,获得10
2秒前
yyf完成签到,获得积分10
2秒前
2秒前
森煜完成签到,获得积分10
4秒前
所所的应助被幽默的羿采纳,获得10
5秒前
6秒前
加油完成签到,获得积分10
6秒前
Fun_112发布了新的文献求助30
6秒前
一十七完成签到 ,获得积分10
8秒前
顾矜的应助被淡淡新竹采纳,获得10
9秒前
Hao发布了新的文献求助10
9秒前
cdercder的应助被开心德地采纳,获得10
9秒前
盒子的应助被是小刘同学呀采纳,获得30
9秒前
10秒前
科研通AI65的应助被wg采纳,获得10
10秒前
理理完成签到,获得积分10
10秒前
CodeCraft的应助被cuipi采纳,获得30
12秒前
白耀庭完成签到,获得积分10
12秒前
12秒前
12秒前
大模型的应助被长风采纳,获得10
13秒前
13秒前
理理发布了新的文献求助10
14秒前
15秒前
15秒前
逆流的鱼完成签到,获得积分10
16秒前
Hello的应助被全没了采纳,获得10
16秒前
李健的应助被柳叶刀采纳,获得20
16秒前
共享精神的应助被时叙采纳,获得10
17秒前
慕青的应助被fmh采纳,获得10
17秒前
无极微光的应助被科研通管家采纳,获得20
17秒前
17秒前
cdercder的应助被开心德地采纳,获得10
17秒前
Maestro_S的应助被科研通管家采纳,获得10
17秒前
小二郎的应助被科研通管家采纳,获得10
18秒前
Jasper的应助被科研通管家采纳,获得10
18秒前
Haru发布了新的文献求助10
18秒前
科目三的应助被科研通管家采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188724
求助须知:如何正确求助?哪些是违规求助? 9576405
关于积分的说明 21847400
捐赠科研通 7786785
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482363